AKKARAJU SRINIVAS sold $1.0M of ALMS (indirect holdings)

Alumis presented Phase III trial results showing its psoriasis drug, envudeucitinib, achieved significant efficacy and safety milestones. The company plans to submit an NDA in Q4 2026, aiming to compete with Bristol Myers Squibb's Sotyktu, which had $291m in 2023 sales.

Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.

Alumis Inc. (ALMS) reported Phase 3 data showing envudeucitinib improved scalp psoriasis, itching, and quality of life in patients. Key findings: 54% achieved complete skin clearance, 80% maintained clear scalp skin, and 40% reported complete itch resolution. The drug was well tolerated. ALMS stock rose 2.95% on Thursday and is up 4.02% in premarket trading.

Alumis (ALMS) reported Phase 3 data for envudeucitinib, showing a 54% PASI 100 response rate at Week 48. The company aims for a 2026 NDA submission. Shares rose 3.49% in pre-market trading to $7.21. According to the CEO, the results support its potential as a leading oral therapy for plaque psoriasis.

Alumis Inc. (ALMS) shared Phase 3 trial data for envudeucitinib, showing 54% of psoriasis patients achieved complete skin clearance at 48 weeks. The drug also demonstrated significant itch reduction and improved quality of life. Alumis plans to file for FDA approval in late 2026.

Alumis Inc. (ALMS) reported Phase 3 data for envudeucitinib, showing 54% PASI 100 at Week 48. The company plans to submit an NDA for moderate-to-severe plaque psoriasis in 4Q 2026, according to the company.